Table 1: Effect of a 16-h pretreatment of 2-DG (20 mM) or hypoxia on reducing the cytotoxic effect of ABCG2 substrate anticancer drug in HCT-116, S1 and S1M1-80.

Drug I C 5 0 ± S D
HCT-116S1S1M1-80

Mitoxantrone (μM)
 Mitoxantrone alone 4 . 2 ± 1 . 2 0 . 1 5 ± 0 . 0 3 4 8 ± 2 . 3
 with 2-DG 9 . 6 ± 1 . 5 0 . 4 8 ± 0 . 0 4 8 0 ± 4 . 1
 in Hypoxia 1 0 . 1 ± 1 . 3 0 . 5 5 ± 0 . 0 4 9 2 ± 7 . 9
 +FTC (5 μM) 5 . 1 ± 1 . 1 0 . 1 3 ± 0 . 0 2 0 . 2 5 ± 0 . 1 0

Cisplatin (μg/mL)
 Cisplatin alone 8 . 3 ± 1 . 1 2 . 4 ± 0 . 9 3 . 3 ± 1 . 1
 with 2-DG 6 . 5 ± 1 . 3 3 . 1 ± 1 . 0 4 . 9 ± 0 . 6
 in Hypoxia 8 . 7 ± 1 . 6 3 . 5 ± 1 . 2 4 . 3 ± 1 . 3
 +FTC (5 μM) 9 . 2 ± 0 . 8 2 . 1 ± 0 . 8 4 . 6 ± 0 . 8

𝑃 < 0 . 0 5 , versus IC50 of the anticancer drug alone.